Recent Event

4th Annual Evercore ISI HealthCONx Conference

Latest Financial Results

Latest Annual Report

For Fiscal Year Ending Dec 31, 2020

mail icon

Sign Up for Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies.

Investor Contact Information

Company

Pieris Pharmaceuticals, Inc.
255 State Street, 9th floor
Boston, MA 02109
USA
T: + 1 (857) 246-8998
info@pieris.com

Investor Relations

Maria Kelman
Executive Director, Investor Relations
T: +1-857-362-9635
kelman@pieris.com

Transfer Agent

Computershare
P.O. Box 30170
College Station, TX 77842-3170
T: 1-877-373-6374 (US, Canada, Puerto Rico) or 1-781-575-3100 (non-US)
web.queries@computershare.com
www.computershare.com/investor